{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:01Z","timestamp":1792643941884,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007791.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000}}],"reference-count":94,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007791.pub5","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:09:23Z","timestamp":1778598563000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological treatments for Friedreich ataxia"],"prefix":"10.1002","volume":"2026","author":[{"given":"Shane","family":"Lyons","sequence":"additional","affiliation":[{"name":"Department of Neurology; University Hospital Waterford; Waterford Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4915-285X","authenticated-orcid":false,"given":"Mary","family":"Kearney","sequence":"additional","affiliation":[{"name":"Department of Neurology; National Ataxia Centre, Tallaght University Hospital; Dublin Ireland"},{"name":"General Practitioner; Irish College of General Practitioners; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Fahey","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Monash University; Clayton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Janjal","sequence":"additional","affiliation":[{"name":"Adjunct Professor, Department of Conservative Dentistry and Endodontics; Saveetha Institute of Medical and Technical Sciences; Chennai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Lakeshore Hospital; Co-Director, Clinical Research Unit (CRU) The Neuro (Montreal Neurological Institute\/Hospital), McGill University; Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Patton","sequence":"additional","affiliation":[{"name":"Research, Policy & Information Department; Irish College of General Practitioners; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"10.1002\/14651858.CD007791.pub5-BIB0001|cit1","unstructured":"Perlman S Recognizing Friedreich ataxia: diagnosis and management Neurology Live"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1186\/s13023-022-02568-3","article-title":"Clinical management guidelines for Friedreich ataxia: best practice in rare diseases","volume":"17","author":"Corben","year":"2022","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/WNL.0000000000006121","article-title":"Nonataxia symptoms in Friedreich: Report from the Registry of the European Friedreich's Ataxia Consortium for Transational Studies (EFACTS)","volume":"91","author":"Reetz","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.29687","article-title":"Predictors of survival in Friedreich's ataxia: a prospective cohort atudy","volume":"3","author":"Indelicato","year":"2024","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub5-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/ana.23698","article-title":"Central role and mechanism of \u00df-cell dysfunction and death in Friedreich ataxia-associated diabetes","volume":"72","author":"Cnop","year":"2012","journal-title":"Annals of Neurology"},{"issue":"16","key":"10.1002\/14651858.CD007791.pub5-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich's ataxia","volume":"335","author":"D\u00fcrr","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana\/25934","article-title":"Safety and efficacy of omaveloxalone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub5-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.12215","article-title":"Prevalence gradients of Friedreich's Ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franci-Cantabrian ice age refuge","volume":"126","author":"Vankan","year":"2013","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"10.1002\/14651858.CD007791.pub5-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s12311-024-01687-w","article-title":"Prevalence and diagnostic journey of Friedreich's ataxia in the state of S\u0101o Paulo, Brazil","volume":"23","author":"Machado","year":"2024","journal-title":"Cerebellum"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub5-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12311-018-0958-x","article-title":"Friedreich ataxia: diagnostic yield and minimal frequency in South Brazil","volume":"18","author":"Fussiger","year":"2019","journal-title":"Cerebellum"},{"issue":"5254","key":"10.1002\/14651858.CD007791.pub5-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.24595","article-title":"Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia","volume":"79","author":"Galea","year":"2016","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub5-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/wnl.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s12311-023-01621-6","article-title":"Therapeutic biomarkers in Friedreich's ataxia: a systematic review and meta-analysis","volume":"23","author":"Gavriilaki","year":"2024","journal-title":"Cerebellum"},{"issue":"8","key":"10.1002\/14651858.CD007791.pub5-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/antiox9080664","article-title":"Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion","volume":"9","author":"Rodr\u00edguez","year":"2020","journal-title":"Antioxidants"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub5-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/jcmn.1308","article-title":"Ferroptosis, a new form of cell death, and its relationship with tumourous diseases","volume":"21","author":"Yu","year":"2017","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"15","key":"10.1002\/14651858.CD007791.pub5-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.94.15_supplement.4147","article-title":"MIN102 (lerglitazone), a brain pentrant PPAR gamma agonist for the treatment of Friedreich's ataxia","volume":"94","author":"Poli","year":"2020","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0018|cit18","unstructured":"Effect of pioglitazone administered to patients with Friedreich's ataxia: proof of concept (ACTFRIE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00811681"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0019|cit19","unstructured":"Study of the effects of pioglitazone in Friedreich ataxia: proof of concept https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003360-19\/FR"},{"issue":"9942","key":"10.1002\/14651858.CD007791.pub5-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open label, dose-escalation study","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub5-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14737175.2020.1821654.","article-title":"Emerging therapies in Friedreich's ataxia","volume":"20","author":"Zesiewicz","year":"2020","journal-title":"Expert Review Neurotharapies"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1535370219890873","article-title":"Effects of tocotrienol supplementation in Friedreich\u2019s ataxia: a model of oxidative stress pathology","volume":"245","author":"Bolotta","year":"2020","journal-title":"Experimental Biology and Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub5-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","article-title":"Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia \u2013 a dose-response trial","volume":"10","author":"Nachbauer","year":"2011","journal-title":"Cerebellum"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub5-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.23435","article-title":"Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit","volume":"26","author":"Sacc\u00e0","year":"2010","journal-title":"Movement Disorder Society"},{"issue":"7","key":"10.1002\/14651858.CD007791.pub5-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/acn3.51971","article-title":"Safety pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia","volume":"11","author":"Clayton","year":"2023","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"8","key":"10.1002\/14651858.CD007791.pub5-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub4","article-title":"Pharmacological treatments in Friedreich ataxia","author":"Kearney","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub5-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub2","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","author":"Kearney","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub5-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub3","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","author":"Kearney","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub5-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791","article-title":"Antioxidants and other pharmacological treatments in Friedreich ataxia","author":"Kearney","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0031|cit31","unstructured":"Higgins JP Savovic J Page MJ Elbers RG Sterne JA Thomas J Chapter 8 Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2019). Cochrane, 2019 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0032|cit32","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub5-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0022-510x(96)00231-6","article-title":"International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome","volume":"145","author":"Trouillas","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub5-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/mds.22660","article-title":"Comparison of three clinical rating scales in Friedreich Ataxia (FRDA)","volume":"24","author":"B\u00fcrk","year":"2009","journal-title":"Movement Disorders"},{"issue":"9","key":"10.1002\/14651858.CD007791.pub5-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/acn3.51118","article-title":"Test\u2013retest reliability of the Friedreich\u2019s ataxia rating scale","volume":"7","author":"Rummey","year":"2020","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"1630","key":"10.1002\/14651858.CD007791.pub5-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9061630","article-title":"Significance of NT-proBNP and high-sensitivity troponin in Freidreich ataxia","volume":"9","author":"Legrand","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub5-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1212\/01.wnl.0000218155.46739.90","article-title":"Measuring Friedreich ataxia: complementary features of examination and performance measures","volume":"66","author":"Lynch","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0038|cit38","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0039|cit39","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0040|cit40","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0041|cit41","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0042|cit42","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2019). Cochrane, 2019 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analysis (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0044|cit44","unstructured":"Sch\u0171nemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-12-S1-470","article-title":"The COMET (Core Outcomes Measures in Effectiveness Trials) Initiative","volume":"12","author":"Williamson","year":"2011","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737175.2024.2310617","article-title":"Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations","volume":"24","author":"Lynch","year":"2024","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub5-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"1","author":"Lynch","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfaa142.P022","article-title":"Kidney effects in the MOXIE trial: a study of omavoloxolone in patients with Friedreich's ataxia","volume":"35","author":"Zaoui","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0049|cit49","unstructured":"Subramony S Lynch D Delatycki M Ferguson D Goldsberry A Khan S Assessment of cardiac safety in patients with Friedreich's ataxia in the MOXIe trial of omaveloxolone Muscular Dystrophy Association Clinical and Science Conference"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub5-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ana.26808","article-title":"Correction to safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"94","author":"Lynch","year":"2023","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/mds.30070","article-title":"Omaveloxolone for the treatment of Friedreich ataxia: efficacy, safety , and future perspectives","volume":"40","author":"Naghipour","year":"2025","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","article-title":"Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia","volume":"270","author":"Lynch","year":"2022","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub5-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and safety of leriglitazone in patients with Friedreich ataxia","volume":"8","author":"Pandolfo","year":"2022","journal-title":"Neurology Genetic"},{"issue":"S27","key":"10.1002\/14651858.CD007791.pub5-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1002\/ana.26180","article-title":"Leriglitazone reduces iron accumulation in the dentate nucleus and improves further relevant disease biomarkers and clinical parameters in a phase 2 clinical study in Friedreich's ataxia (FRDA)","volume":"90","author":"Pandolfo","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0055|cit55","unstructured":"Minoryx Therapeutics BE SA Clinical study protocol, a double-blind, placebo-controlled study on the effects of MIN-102 on biochemical, imaging, neurophysiological and clinical markers in patients with Friedreich's Ataxia https:\/\/cdn-links.lww.com\/permalink\/nxg\/a\/nxg_2022_09_21_martinell_1_sdc1.pdf"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0056|cit56","unstructured":"Reis JD LS mean change, standard deviation and mean of SARA, ADL, CCF [personal communication] Email to: M Kearney"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0058|cit58","unstructured":"Cooper MJ Friedreich's ataxia study Cooper 2008 [personal communication] Email to: M Kearney"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1212\/01.WNL.0000055872.50364.FC","article-title":"Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial","volume":"60","author":"Mariotti","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0060|cit60","unstructured":"Mariotti C Idebenone trial [personal communication] Email to: M Kearney"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0061|cit61","unstructured":"A study of efficacy, safety and tolerability of idebenone in the treatment of Friedreich's ataxia (FRDA) patients http:\/\/clinicaltrials.gov\/study\/NCT00905268"},{"issue":"29","key":"10.1002\/14651858.CD007791.pub5-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCULATIONAHA.111.059477","article-title":"The heart in Friedreich ataxia: definiton of cardiomyopathy, disease severity, and correlation with neuological symptoms","volume":"2","author":"Weidemann","year":"2012","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0063|cit63","unstructured":"A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004083-22\/GB"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0064|cit64","unstructured":"Santhera Pharmaceuticals Holding AG Santhera Mitochondrial Protection with Idebenne in Cardiac or Neurological Outcome Study (MICONOS) trial with Catena\u00a9\/Sovtima\u00a9 in Friedreich's ataxia misses primary endpoint https:\/\/lacaf.org\/en\/santhera-trial-with-catena-in-friedreich-ataxia-misses-primary-endpoint\/"},{"issue":"5","key":"10.1002\/14651858.CD007791.pub5-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long-term effect of epoetin alpfa on clinical and biochemical markers in Freidreich ataxia","volume":"31","author":"Sacc\u00e0","year":"2016","journal-title":"Movement Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007791.pub5-BIB0066|cit66","first-page":"638","article-title":"Improvement in upright stability subscale of mFARS with vatiquinone treatment in MOVE-FA: a phase 3, double-blind placebo-controlled trial","volume":"39","author":"Lynch","year":"2024","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0067|cit67","unstructured":"A study to assess the efficacy and safety of vatiquinone for the treatemnt of participants with Friedreich ataxia (MOVE-FA) https:\/\/clinicaltrials.gov\/study\/NCT04577352"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0068|cit68","unstructured":"Vatiquinone treatment shows benefit across end points for Friedreich ataxia in phase 3 MOVE-FA trial Muscular Dystrophy Association Clinical and Scientific Conference 2024"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0069|cit69","unstructured":"A study to find out how BIIB141 (omaveloxolone) is processed in the body and to learn more about its safety in participants with Friedreich's ataxia aged 2 to 15 years old https:\/\/clinicaltrials.gov\/study\/NCT06054893"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0070|cit70","unstructured":"NAD+ and exercise in FA https:\/\/Clinicaltrials.gov\/study\/NCT04192136"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0071|cit71","unstructured":"A study to assess nomlabofusp in adolescents and children with Friedreich's ataxia https:\/\/clinicaltrials.gov\/study\/NCT06681766"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0072|cit72","unstructured":"Gene therapy for cardiomyopathy associated with Friedreich's ataxia https:\/\/clinicaltrials.gov\/study\/NCT05445323"},{"issue":"7","key":"10.1002\/14651858.CD007791.pub5-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/mds.29808","article-title":"Calcitriol treatment is safe and increases frataxin levels in Friedreich ataxia patients","volume":"39","author":"Alemany-Perma","year":"2024","journal-title":"Movement Disorders"},{"issue":"9","key":"10.1002\/14651858.CD007791.pub5-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.29970","article-title":"Calcitriol in Friedreich ataxia","volume":"39","author":"McCormack","year":"2024","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub5-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/acn3.731","article-title":"Randomized, double-blind, placebo-controlled study of interferon-c 1b in Friedreich Ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0076|cit76","unstructured":"Micronised resveratrol as a treatment for Friedreich ataxia https:\/\/clinicaltrials.gov\/study\/NCT03933163"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"0","DOI":"10.3389\/fnins.2023.1260977","article-title":"Rationale and protocol of a double-blind, randomized, placebo-controlled trail to test the efficacy, safety and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201)","volume":"17","author":"Pane","year":"2023","journal-title":"Frontiers in Neuroscience"},{"issue":"8","key":"10.1002\/14651858.CD007791.pub5-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/children11080958","article-title":"A pilot phase 3 randomized trial to evaluate the safety and potential efficacy of etravirine in Friedreich ataxia patients","volume":"11","author":"Paparella","year":"2024","journal-title":"Children"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Vavla M D'Angelo MG Safety and Efficacy of Interferon \u03b3 in Friedreich's Ataxia International Parkinson and Movement Disorder Society 2020 10.1002\/mds.27979","DOI":"10.1002\/mds.27979"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0080|cit80","unstructured":"Study of the efficacy and safety of nicotamide in patients with Friedreich ataxia (NICOFA) https:\/\/clinicaltrials.gov\/study\/NCT03761511"},{"issue":"33","key":"10.1002\/14651858.CD007791.pub5-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-019-0038-9","article-title":"Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)","volume":"1","author":"Reetz","year":"2019","journal-title":"Neurological Research and Practice"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub5-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000039.pub2","article-title":"Eliciting adverse effects data from participants in clinical trials","author":"Allen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40263-024-01113-z","article-title":"New and emerging drug gene therapies for Friedreich ataxia","volume":"38","author":"Scott","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2022.02.008","article-title":"Gene therapy for Friedreich ataxia: too much, too little, or just right?","volume":"25","author":"Payne","year":"2022","journal-title":"Molecular Therapy: Methods & Clinicial Development"},{"issue":"Suppl","key":"10.1002\/14651858.CD007791.pub5-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"106043","DOI":"10.1016\/j.nmd.2025.106043","article-title":"234PLong-term use of omaveloxolone in patients with Friedreich ataxia: up to 5 years of natural history propensity score matching from the MOXIe OLE","volume":"53","author":"Nachbauer","year":"2025","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub5-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"32","DOI":"10.17925\/USN.2022.18.1.32","article-title":"Emerging therapies in Friedreich's ataxia: a review","volume":"18","author":"Perlman","year":"2022","journal-title":"touchREVIEWS in Neurology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0087|cit87","unstructured":"Wilmot G Mariotti C Lynch D Tai G Pandolfo M Chapter 2 Potential disease modifying therapies for Friedreich ataxia in Clinical Management Guidelines for Friedreich Ataxia; November 2024 Available at https:\/\/frdaguidelines.org\/wp-content\/uploads\/2024\/12\/2.-Overview-disease-modifying-therapies_Update_November-2024.pdf 2024"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub5-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/mds.30070","article-title":"Omaveloxolone for the treatment of Friedreich ataxia: efficacy, safety, and future perspectives","volume":"40","author":"Naghipour","year":"2024","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub5-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2023.2276758","article-title":"Experimental drugs for Friedrich's ataxia: progress and setbacks in clinical trials","volume":"32","author":"Boesch","year":"2023","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0090|cit90","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0091|cit91","unstructured":"Friedreich Ataxia Global Clinical Consortium unified natural history study (UNIFAI) https:\/\/clinicaltrials.gov\/study\/NCT06016946"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1109\/TNSRE.2021.3214869","article-title":"Objective assessment of progression and disease characterization of Friedreich ataxia via an instrumented drinking cup: preliminary results","volume":"29","author":"Krishna","year":"2021","journal-title":"Institute of Electrical and Electronic Engineers, Transactions on Neural Systems and Rehabilitation Engineering"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar2024.1342965","article-title":"Accelerometer-based measures in Friedreich ataxia: a longitudinal study on real-life activity","volume":"15","author":"Fichera","year":"2024","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD007791.pub5-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2025.1560808","article-title":"Editorial: the mechanistic investigation and emerging therapies for Friedreich's ataxia","volume":"16","author":"Dong","year":"2025","journal-title":"Frontiers in Pharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:04:40Z","timestamp":1792641880000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007791.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007791.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}